Abstract

Drug products adapted for nasal delivery, comprising a device filled with a pharmaceutical composition comprising naltrexone are provided. Formulations and methods of treating alcohol use disorder and related conditions with the drug products are also provided.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61K 47/02 - Inorganic compounds
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61P 25/32 - Alcohol-abuse
• A61P 25/36 - Opioid-abuse

Abstract

Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising naltrexone are provided. Formulations and methods of treating alcohol use disorder and related conditions with the drug products are also provided.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions
• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 47/02 - Inorganic compounds
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61M 11/00 - Sprayers or atomisers specially adapted for therapeutic purposes
• A61M 15/00 - Inhalators
• A61M 15/06 - Inhaling appliances shaped like cigars, cigarettes or pipes
• A61M 15/08 - Inhaling devices inserted into the nose
• A61P 25/32 - Alcohol-abuse

Goods & Services

(1) Printed matter, namely, information cards, leaflets and pamphlets in the field of opioid and other substance use addiction, dependence, prevention, and treatment (1) Providing an interactive web site featuring technology that enables users to locate and access treatments for addiction and to track, monitor and generate addiction treatment information and reports (2) Charitable services, namely, donating medicine to underserved communities; Charitable services, namely, donating medications for the treatment of opioid and other substance use addiction to underserved communities; Providing medical information; Provision of information about pharmaceuticals used in the treatment and prevention of opioid and other substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose; Provision of medical information and advice via a website in the field of opioid and other substance use addiction and its treatment; Provision of medical information and advice in the field of opioid and other substance use dependence and its treatment; Provision of health care information and advice; Provision of pharmaceutical information and advice for medical purposes

Goods & Services

Printed matter, namely, information cards, leaflets and pamphlets in the field of opioid and other substance use addiction, dependence, prevention, and treatment Providing an interactive web site featuring technology that enables users to locate and access treatments for addiction and to track, monitor and generate addiction treatment information and reports Charitable services, namely, donating medicine to underserved communities; Charitable services, namely, donating medications for the treatment of opioid and other substance use addiction to underserved communities; Providing medical information; Provision of information about pharmaceuticals used in the treatment and prevention of opioid and other substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose; Provision of medical information and advice via a website in the field of opioid and other substance use addiction and its treatment; Provision of medical information and advice in the field of opioid and other substance use dependence and its treatment; Provision of health care information and advice; Provision of pharmaceutical information and advice for medical purposes

Goods & Services

Printed matter, namely, information cards, leaflets and pamphlets in the field of opioid and other substance use addiction, dependence, prevention, and treatment Providing an interactive web site featuring technology that enables users to locate and access treatments for addiction and to track, monitor and generate addiction treatment information and reports Charitable services, namely, donating medicine to underserved communities; Charitable services, namely, donating medications for the treatment of opioid and other substance use addiction to underserved communities; Providing medical information; Provision of information about pharmaceuticals used in the treatment and prevention of opioid and other substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose; Provision of medical information and advice via a website in the field of opioid and other substance use addiction and its treatment; Provision of medical information and advice in the field of opioid and other substance use dependence and its treatment; Provision of health care information and advice; Provision of pharmaceutical information and advice for medical purposes

Goods & Services

Pharmaceutical delivery systems, namely, implantable liquid that forms a sponge-like solid in situ used with various medications for sustained release of medication into the body Printed matter, namely, information cards, leaflets and pamphlets in the field of opioid and other substance use addiction, dependence, prevention, and treatment

Goods & Services

Pharmaceutical preparations and substances in this class. Provision of pharmaceutical advice and information about pharmaceuticals used in the treatment and prevention of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment and prevention of co-morbidities associated with substance use disorders, for the treatment and prevention of mental health diseases and disorders, for the treatment and prevention of central nervous system disease and disorders, and for the treatment of pain; health counseling; provision of health care information and advice; provision of pharmaceutical information and advice; provision of information and advice in the field of opioid dependence; providing pharmaceutical information regarding medication information and treatment plans.

Abstract

A medication component mixing system is formed of a first syringe, such as a female syringe, and a second syringe such as a male syringe, wherein the system is configured to mix a female portion and a male portion of the medication. The female syringe and the male syringe mechanically couple to one another in an end-to-end fashion for mixing of the contents of the female and male portions.

IPC Classes  ?

• A61J 1/20 - Arrangements for transferring fluids, e.g. from vial to syringe
• A61M 5/178 - Syringes
• A61M 5/31 - Syringes Details

Abstract

The present invention relates to a risperidone sustained release delivery system for treatment of medical conditions relating to delusional psychosis, schizophrenia, bipolar disorder, psychotic depression, obsessive-compulsion disorder, Tourette syndrome, and autistic spectrum disorders. The sustained release delivery system includes a flowable composition containing risperidone, a metabolite, or a prodrug thereof and an implant containing risperidone, a metabolite, or a prodrug thereof. The flowable composition may be injected into tissue whereupon it coagulates to become a solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid, and risperidone, a metabolite or a prodrug thereof.

IPC Classes  ?

• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers

Goods & Services

Pharmaceutical preparations and substances in this class. Provision of pharmaceutical advice and information about pharmaceuticals used in the treatment and prevention of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment and prevention of co-morbidities associated with substance use disorders, for the treatment and prevention of mental health diseases and disorders, for the treatment and prevention of central nervous system disease and disorders, and for the treatment of pain; health counseling; provision of health care information and advice; provision of pharmaceutical information and advice; provision of information and advice in the field of opioid dependence; providing pharmaceutical information regarding medication information and treatment plans.

Abstract

The disclosure provides a dosage regimen using sustained-release buprenorphine formulations to produce therapeutic levels of buprenorphine in patients for the treatment of pain or opioid use disorders.

IPC Classes  ?

• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Abstract

Disclosed herein are formulations and methods for reversing one or more symptoms of cannabinoid overdose, comprising parenterally administering a CB1 antagonist in an amount sufficient to reverse the cannabinoid overdose symptoms.

IPC Classes  ?

• A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
• A61K 9/00 - Medicinal preparations characterised by special physical form

Goods & Services

Printed matter in the field of opioid and other substance use addiction, dependence, prevention, and treatment. Healthcare; medical information; provision of medical information and advice via a website in the field of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose; provision of medical information and advice in the field of opioid dependence, and treatment of and recovery from opioid dependence; provision of health care information and advice; provision of pharmaceutical information and advice for medical purposes.

Goods & Services

Printed matter in the field of opioid and other substance use addiction, dependence, prevention, and treatment. Healthcare; medical information; provision of medical information and advice via a website in the field of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose; provision of medical information and advice in the field of opioid dependence, and treatment of and recovery from opioid dependence; provision of health care information and advice; provision of pharmaceutical information and advice for medical purposes.

Goods & Services

Provision of health care advice; providing information relating to opioid dependence

Goods & Services

(1) Printed matter in the field of opioid and other substance use addiction, dependence, prevention, and treatment. (1) Healthcare; medical information; provision of medical information and advice via a website in the field of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose; provision of medical information and advice in the field of opioid dependence, and treatment of and recovery from opioid dependence; provision of health care information and advice; provision of pharmaceutical information and advice for medical purposes.

Goods & Services

Printed matter, namely, information cards, leaflets and pamplets in the field of opioid and other substance use addiction, dependence, prevention, and treatment Healthcare; medical information; provision of medical information and advice via a website in the field of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose; provision of medical information and advice in the field of opioid dependence, and treatment of and recovery from opioid dependence; provision of health care information and advice; provision of pharmaceutical information and advice for medical purposes

Goods & Services

(1) Printed matter in the field of opioid and other substance use addiction, dependence, prevention, and treatment. (1) Healthcare; medical information; provision of medical information and advice via a website in the field of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose; provision of medical information and advice in the field of opioid dependence, and treatment of and recovery from opioid dependence; provision of health care information and advice; provision of pharmaceutical information and advice for medical purposes.

Goods & Services

Printed matter, namely, information cards, leaflets and pamphlets in the field of opioid and other substance use addiction, dependence, prevention, and treatment Healthcare; medical information; provision of medical information and advice via a website in the field of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose; provision of medical information and advice in the field of opioid dependence, and treatment of and recovery from opioid dependence; provision of health care information and advice; provision of pharmaceutical information and advice for medical purposes

Abstract

The present invention relates to a risperidone sustained release delivery system for treatment of medical conditions relating to delusional psychosis, schizophrenia, bipolar disorder, psychotic depression, obsessive-compulsion disorder, Tourette syndrome, and autistic spectrum disorders. The sustained release delivery system includes a flowable composition containing risperidone, a metabolite, or a prodrug thereof and an implant containing risperidone, a metabolite, or a prodrug thereof. The flowable composition may be infected into tissue whereupon it coagulates to become a solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid, and risperidone, a metabolite or a prodrug thereof.

IPC Classes  ?

• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers

Goods & Services

Pharmaceutical preparations for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; medicines for human and veterinary purposes, namely, medicines for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; pharmaceutical preparations for use in the treatment of chemical addictions. Provision of pharmaceutical advice and information about pharmaceuticals used in the treatment and prevention of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment and prevention of co-morbidities associated with substance use disorders, for the treatment and prevention of mental health diseases and disorders, for the treatment and prevention of central nervous system disease and disorders, and for the treatment of pain; health counseling; provision of health care information and advice; provision of pharmaceutical information and advice; providing pharmaceutical information regarding medication information and treatment plans.

Abstract

The disclosure provides a dosage regimen using sustained-release buprenorphine formulations to produce therapeutic levels of buprenorphine in patients for the treatment of pain or opioid use disorders.

IPC Classes  ?

• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Abstract

The disclosure provides methods for treating, preventing, and reducing the incidence of opioid-induced respiratory depression, opioid-induced apnea, and opioid overdose in patients by administering buprenorphine or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

The disclosure provides methods for treating negative, positive, and general symptoms of schizophrenia in patients using long-acting, injectable antipsychotic drugs. The disclosure provides methods of treating a negative symptom in a schizophrenic patient in need thereof by administering to the patient a therapeutically effective amount of a risperidone composition; wherein the risperidone composition comprises about 120 mg of risperidone base.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia

Goods & Services

(1) Pharmaceutical preparations; medicines for human and veterinary purposes; pharmaceutical preparations for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; medicines for human and veterinary purposes, namely, medicines for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain (2) Medical and veterinary apparatus; Medical apparatus for diagnosing or treating substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, and for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain (1) Medical services; health care; medical clinic services; medical research services; health counselling; provision of health care information and advice; provision of pharmaceutical information and advice; provision of pharmaceutical advice and information about pharmaceuticals used in the treatment and prevention of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment and prevention of co-morbidities associated with substance use disorders, for the treatment and prevention of mental health diseases and disorders, for the treatment and prevention of central nervous system disease and disorders, and for the treatment of pain

Goods & Services

(1) Healthcare; medical information; provision of medical information and advice via a website in the field of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose; provision of medical information and advice in the field of opioid dependence, and treatment of and recovery from opioid dependence; provision of health care information and advice; provision of pharmaceutical information and advice for medical purposes

Goods & Services

(1) Healthcare; medical information; provision of medical information and advice via a website in the field of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose; provision of medical information and advice in the field of opioid dependence, and treatment of and recovery from opioid dependence; provision of health care information and advice; provision of pharmaceutical information and advice for medical purposes

Abstract

Drug products adapted for nasal delivery comprising naltrexone, alone or in combination with excipients, are provided. Pre-primed devices for intranasal administration of the drug products are also provided. In addition, methods for treating and preventing a variety of opioid receptor-mediated diseases, disorders, addictions, symptoms, reward-based behaviors, and conditions with the drugs products are provided

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 25/36 - Opioid-abuse
• A61K 9/08 - Solutions
• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61K 47/02 - Inorganic compounds
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Abstract

Disclosed herein are formulations and methods for reversing one or more symptoms of cannabinoid hyperemesis syndrome (CHS) or one or more symptoms thereof, comprising parenterally administering a CB1 antagonist in an amount sufficient to reverse the CHS or symptom(s).

IPC Classes  ?

• A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

Provided are formulations and methods for treating, reversing, or reducing acute cannabinoid overdose, cannabinoid hyperemesis syndrome, or one or more symptoms thereof, comprising parenterally administering a CB1 antagonist in an amount sufficient to reverse the acute cannabinoid overdose, cannabinoid hyperemesis syndrome, or symptom(s) thereof.

IPC Classes  ?

• A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
• A61K 9/107 - Emulsions
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 39/02 - Antidotes

Goods & Services

Healthcare; medical information; provision of medical information and advice via a website in the field of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose; provision of medical information and advice in the field of opioid dependence, and treatment of and recovery from opioid dependence; provision of health care information and advice; provision of pharmaceutical information and advice for medical purposes

Goods & Services

Providing an interactive web site featuring technology that enables users to search, locate and access health care and medical service providers; providing an interactive web site featuring technology that enables users to search, locate and access injection administration service providers Provision of health care information and advice; Provision of pharmaceutical information and advice for medical purposes; provision of health care information and advice relating to administration of pharmaceutical injectables

Goods & Services

Healthcare; medical information; provision of medical information and advice via a website in the field of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose; provision of medical information and advice in the field of opioid dependence, and treatment of and recovery from opioid dependence; provision of health care information and advice; provision of pharmaceutical information and advice for medical purposes

Abstract

The disclosure provides methods for treating negative, positive, and general symptoms of schizophrenia in patients using long-acting, injectable antipsychotic drugs. The disclosure provides methods of treating a negative symptom in a schizophrenic patient in need thereof by administering to the patient a therapeutically effective amount of a risperidone composition; wherein the risperidone composition comprises about 120 mg of risperidone base.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia

Abstract

The disclosure provides methods for treating negative, positive, and general symptoms of schizophrenia in patients using long-acting, injectable antipsychotic drugs. The disclosure provides methods of treating a negative symptom in a schizophrenic patient in need thereof by administering to the patient a therapeutically effective amount of a risperidone composition; wherein the risperidone composition comprises about 120 mg of risperidone base.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia

Abstract

Drug products adapted for nasal delivery, comprising a device filled with a pharmaceutical composition comprising naltrexone are provided. Formulations and methods of treating alcohol use disorder and related conditions with the drug products are also provided.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 38/00 - Medicinal preparations containing peptides
• A61M 11/00 - Sprayers or atomisers specially adapted for therapeutic purposes

Abstract

Disclosed herein are formulations and methods for reversing cannabinoid overdose or one or more symptoms thereof, comprising parenterally administering a CB1 antagonist in an amount sufficient to reverse the cannabinoid overdose or symptom(s).

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
• A61K 31/415 - 1,2-Diazoles

Abstract

Disclosed herein are formulations and methods for reversing cannabinoid overdose or one or more symptoms thereof, comprising parenterally administering a CB1 antagonist in an amount sufficient to reverse the cannabinoid overdose or symptom(s).

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine

Abstract

The disclosure provides methods for treating, preventing, and reducing the incidence of opioid- induced respiratory depression, opioid-induced apnea, and opioid overdose in patients by administering buprenorphine or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The disclosure provides methods for treating, preventing, and reducing the incidence of opioid- induced respiratory depression, opioid-induced apnea, and opioid overdose in patients by administering buprenorphine or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• A61P 11/06 - Antiasthmatics
• A61P 11/08 - Bronchodilators
• C07D 489/02 - Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone

Abstract

The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.

IPC Classes  ?

• G06F 3/06 - Digital input from, or digital output to, record carriers
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• G06F 16/11 - File system administration, e.g. details of archiving or snapshots
• G06F 9/48 - Program initiatingProgram switching, e.g. by interrupt
• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 31/4748 - QuinolinesIsoquinolines forming part of bridged ring systems

Abstract

min ratio of less than 200 and a lag time less than 0.2.

IPC Classes  ?

• A61K 9/14 - Particulate form, e.g. powders
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
• A61K 9/06 - OintmentsBases therefor
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets

Abstract

The present invention relates to products and methods for treatment of narcotic dependence in a user. The invention more particularly relates to self-supporting dosage forms which provide an active agent for treating narcotic dependence while providing sufficient buccal adhesion of the dosage form.

IPC Classes  ?

• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/4355 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
• A61K 9/70 - Web, sheet or filament bases
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 31/46 - 8-Azabicyclo [3.2.1] octaneDerivatives thereof, e.g. atropine, cocaine
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/38 - CelluloseDerivatives thereof

Abstract

The present invention relates to a risperidone sustained release delivery system for treatment of medical conditions relating to delusional psychosis, schizophrenia, bipolar disorder, psychotic depression, obsessive-compulsion disorder, Tourette syndrome, and autistic spectrum disorders. The sustained release delivery system includes a flowable composition containing risperidone, a metabolite, or a prodrug thereof and an implant containing risperidone, a metabolite, or a prodrug thereof. The flowable composition may be injected into tissue whereupon it coagulates to become a solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid, and risperidone, a metabolite or a prodrug thereof.

IPC Classes  ?

• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers

Abstract

A medication component mixing system is formed of a first syringe, such as a female syringe, and a second syringe such as a male syringe, wherein the system is configured to mix a female portion and a male portion of the medication. The female syringe and the male syringe mechanically couple to one another in an end-to-end fashion for mixing of the contents of the female and male portions.

IPC Classes  ?

• A61J 1/20 - Arrangements for transferring fluids, e.g. from vial to syringe
• A61M 5/178 - Syringes
• A61M 5/31 - Syringes Details

Abstract

A medication component mixing system is formed of a first syringe, such as a female syringe, and a second syringe such as a male syringe, wherein the system is configured to mix a female portion and a male portion of the medication. The female syringe and the male syringe mechanically couple to one another in an end-to-end fashion for mixing of the contents of the female and male portions.

IPC Classes  ?

• A61J 1/20 - Arrangements for transferring fluids, e.g. from vial to syringe
• A61M 5/178 - Syringes
• A61M 5/31 - Syringes Details
• A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
• A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles

Abstract

A medication component mixing system is formed of a first syringe, such as a female syringe, and a second syringe such as a male syringe, wherein the system is configured to mix a female portion and a male portion of the medication. The female syringe and the male syringe mechanically couple to one another in an end-to-end fashion for mixing of the contents of the female and male portions.

IPC Classes  ?

• A61M 5/31 - Syringes Details
• A61M 5/178 - Syringes
• A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
• A61J 1/20 - Arrangements for transferring fluids, e.g. from vial to syringe

Goods & Services

(1) Pharmaceutical preparations for the treatment of mental health diseases and disorders, for the treatment of the central nervous system, namely, brain diseases, central nervous system movement disorders, ocular mobility disorders, spinal cord diseases, schizophrenia, and central nervous system perception disorders, central nervous system feeling disorders, and central nervous system behavioral disorders; medicines for human and veterinary purposes, namely, medicines for the treatment of mental health diseases and disorders, for the treatment of the central nervous system, namely, brain diseases, central nervous system movement disorders, ocular mobility disorders, spinal cord diseases, schizophrenia, and central nervous system perception disorders, central nervous system feeling disorders, and central nervous system behavioral disorders

Goods & Services

(1) Pharmaceutical preparations for the treatment of mental health diseases and disorders, for the treatment of the central nervous system, namely, brain diseases, central nervous system movement disorders, ocular mobility disorders, spinal cord diseases, schizophrenia, and central nervous system perception disorders, central nervous system feeling disorders, and central nervous system behavioral disorders; medicines for human and veterinary purposes, namely, medicines for the treatment of mental health diseases and disorders, for the treatment of the central nervous system, namely, brain diseases, central nervous system movement disorders, ocular mobility disorders, spinal cord diseases, schizophrenia, and central nervous system perception disorders, central nervous system feeling disorders, and central nervous system behavioral disorders

Abstract

The disclosure is directed to novel dopamine D3 receptor antagonists, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, including treating drug dependency and psychosis.

IPC Classes  ?

• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems
• C07D 493/08 - Bridged systems

Abstract

The disclosure provides compounds having formula (I), where the substituents are as defined herein. The compounds are useful for modulating the dopamine D3 receptor and for treating conditions associated therewith, such as addictions, drug dependency, and psychiatric conditions.

IPC Classes  ?

• A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
• C07D 487/04 - Ortho-condensed systems
• C07D 498/04 - Ortho-condensed systems
• A61P 25/36 - Opioid-abuse
• A61P 25/32 - Alcohol-abuse
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• C07D 209/52 - Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered

Goods & Services

Pharmaceutical preparations for the treatment of mental health diseases and disorders; Medicines for human and veterinary purposes, namely, medicines for the treatment of mental health diseases and disorders

Abstract

The disclosure provides extended release pharmaceutical formulations comprising an opioid, particularly buprenorphine, a biocompatible organic solvent, and, optionally, a glycol, for use in the treatment of pain or opioid dependence. The pharmaceutical formulations are in the form of a pharmaceutical solution.

IPC Classes  ?

• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61K 9/08 - Solutions
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Abstract

The disclosure provides sustained-release buprenorphine formulations that produce therapeutic plasma concentration levels of buprenorphine in patients to treat opioid use disorder.

IPC Classes  ?

• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 25/36 - Opioid-abuse
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Abstract

The disclosure provides sustained-release buprenorphine formulations that produce therapeutic plasma concentration levels of buprenorphine in patients to treat opioid use disorder.

IPC Classes  ?

• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61P 25/36 - Opioid-abuse

Abstract

The disclosure provides buprenorphine formulations that produce therapeutic plasma concentration levels of buprenorphine in patients to treat opioid use disorder, to reduce or eliminate opioid withdrawal symptoms, to reduce or eliminate opioid craving, and to induce and maintain opioid abstinence.

IPC Classes  ?

• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

min ratio of less than 200 and a lag time less than 0.2.

IPC Classes  ?

• A61K 9/14 - Particulate form, e.g. powders
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
• A61K 9/06 - OintmentsBases therefor
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets

Abstract

3 receptors, such as treating substance abuse or psychiatric diseases.

IPC Classes  ?

• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings

Abstract

The disclosure is directed to novel dopamine D3 receptor antagonists, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, including treating drug dependency and psychosis.

IPC Classes  ?

• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 493/08 - Bridged systems
• C07D 471/04 - Ortho-condensed systems
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

3 receptor and for treating conditions associated therewith, such as addictions, drug dependency, and psychiatric conditions.

IPC Classes  ?

• A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
• A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
• C07D 209/02 - Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
• C07D 487/04 - Ortho-condensed systems
• C07D 498/04 - Ortho-condensed systems
• A61P 25/36 - Opioid-abuse
• A61P 25/32 - Alcohol-abuse
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• C07D 209/52 - Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered

Abstract

The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 31/4748 - QuinolinesIsoquinolines forming part of bridged ring systems
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• G06F 3/06 - Digital input from, or digital output to, record carriers
• G06F 16/11 - File system administration, e.g. details of archiving or snapshots
• G06F 9/48 - Program initiatingProgram switching, e.g. by interrupt

Abstract

The present invention relates to a risperidone sustained release delivery system for treatment of medical conditions relating to delusional psychosis, schizophrenia, bipolar disorder, psychotic depression, obsessive-compulsion disorder, Tourette syndrome, and autistic spectrum disorders. The sustained release delivery system includes a flowable composition containing risperidone, a metabolite, or a prodrug thereof and an implant containing risperidone, a metabolite, or a prodrug thereof. The flowable composition may be injected into tissue whereupon it coagulates to become a solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid, and risperidone, a metabolite or a prodrug thereof.

IPC Classes  ?

• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/51 - Thiamines, e.g. vitamin B1
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Abstract

Drug products adapted for nasal delivery comprising naltrexone, alone or in combination with excipients, are provided. Pre-primed devices for intranasal administration of the drug products are also provided. In addition, methods for treating and preventing a variety of opioid receptor-mediated diseases, disorders, addictions, symptoms, reward-based behaviors, and conditions with the drugs products are provided.

IPC Classes  ?

• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions
• A61M 15/08 - Inhaling devices inserted into the nose
• A61P 25/36 - Opioid-abuse

Abstract

The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61K 31/4748 - QuinolinesIsoquinolines forming part of bridged ring systems
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• G06F 3/06 - Digital input from, or digital output to, record carriers
• G06F 9/48 - Program initiatingProgram switching, e.g. by interrupt
• G06F 17/30 - Information retrieval; Database structures therefor

Abstract

Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising naltrexone are provided. Formulations and methods of treating alcohol use disorder and related conditions with the drug products are also provided.

IPC Classes  ?

• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61K 9/08 - Solutions
• A61M 11/00 - Sprayers or atomisers specially adapted for therapeutic purposes
• A61P 25/32 - Alcohol-abuse

Goods & Services

Pharmaceutical preparations for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; medicines for human and veterinary purposes, namely, medicines for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; Pharmaceutical preparations for use in the treatment of chemical addictions. Provision of pharmaceutical advice and information about pharmaceuticals used in the treatment and prevention of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment and prevention of co-morbidities associated with substance use disorders, for the treatment and prevention of mental health diseases and disorders, for the treatment and prevention of central nervous system disease and disorders, and for the treatment of pain; health counseling; provision of health care information and advice; provision of pharmaceutical information and advice; providing pharmaceutical information regarding medication information and treatment plans.

Goods & Services

Pharmaceutical preparations for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; medicines for human and veterinary purposes, namely, medicines for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; Pharmaceutical preparations for use in the treatment of chemical addictions. Provision of pharmaceutical advice and information about pharmaceuticals used in the treatment and prevention of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment and prevention of co-morbidities associated with substance use disorders, for the treatment and prevention of mental health diseases and disorders, for the treatment and prevention of central nervous system disease and disorders, and for the treatment of pain; health counseling; provision of health care information and advice; provision of pharmaceutical information and advice; providing pharmaceutical information regarding medication information and treatment plans.

Goods & Services

Pharmaceutical preparations for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; medicines for human and veterinary purposes, namely, medicines for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; Pharmaceutical preparations for use in the treatment of chemical addictions. Provision of pharmaceutical advice and information about pharmaceuticals used in the treatment and prevention of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment and prevention of co-morbidities associated with substance use disorders, for the treatment and prevention of mental health diseases and disorders, for the treatment and prevention of central nervous system disease and disorders, and for the treatment of pain; health counseling; provision of health care information and advice; provision of pharmaceutical information and advice; providing pharmaceutical information regarding medication information and treatment plans.

Abstract

The disclosure provides a dosage regimen using sustained-release buprenorphine formulations to produce therapeutic levels of buprenorphine in patients for the treatment of pain or opioid use disorders.

IPC Classes  ?

• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Abstract

The disclosure is directed to novel dopamine D3 receptor antagonists, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, including treating drug dependency and psychosis.

IPC Classes  ?

• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems
• C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 493/08 - Bridged systems
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.

IPC Classes  ?

• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 31/4748 - QuinolinesIsoquinolines forming part of bridged ring systems
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Goods & Services

(1) Printed products, namely, pamphlets and flyers in the field of opioid dependence and its treatment (1) Providing temporary use of a web-based software application for accessing, operating, and using a treatment participant engagement portal via an interactive website that provides healthcare related information, tools and resources, namely, information relating to health insurance, information relating to financial assistance programs and alternate funding resources in the field of healthcare, copay assistance programs, insurance benefit investigations, insurance coverage reports, insurance case management services, medication savings cards, insurance forms and letters, treatment and health plan provider location services, insurance claim submission and reimbursement assistance services, denied claim review and research services, and insurance verification services, and facilitates communications, connectivity, and workflow with healthcare providers, healthcare organizations and patients in the field of medicine and pharmaceuticals; hosting a website featuring an online community for registered users to participate in discussions and form virtual communities to engage in social networking services in the fields of opioid dependence and schizophrenia, and request and provide feedback on services relating to the treatment of opioid dependence and schizophrenia (2) Provision of information and advice via a website in the field of opioid dependence and its treatment; provision of information and advice in the field of opioid dependence and its treatment; provision of health care information and advice in the fields of opioid dependence, schizophrenia, and their treatment; provision of pharmaceutical information and advice; providing health care information via an interactive web site featuring technology that enables users to enter, access, track, monitor and generate addiction treatment information and reports

Goods & Services

(1) Printed products, namely, pamphlets and flyers in the field of opioid dependence and its treatment (1) Providing temporary use of a web-based software application for accessing, operating, and using a treatment participant engagement portal via an interactive website that provides healthcare related information, tools and resources, namely, information relating to health insurance, information relating to financial assistance programs and alternate funding resources in the field of healthcare, copay assistance programs, insurance benefit investigations, insurance coverage reports, insurance case management services, medication savings cards, insurance forms and letters, treatment and health plan provider location services, insurance claim submission and reimbursement assistance services, denied claim review and research services, and insurance verification services, and facilitates communications, connectivity, and workflow with healthcare providers, healthcare organizations and patients in the field of medicine and pharmaceuticals; hosting a website featuring an online community for registered users to participate in discussions and form virtual communities to engage in social networking services in the fields of opioid dependence and schizophrenia, and request and provide feedback on services relating to the treatment of opioid dependence and schizophrenia (2) Provision of information and advice via a website in the field of opioid dependence and its treatment; provision of information and advice in the field of opioid dependence and its treatment; provision of health care information and advice in the fields of opioid dependence, schizophrenia, and their treatment; provision of pharmaceutical information and advice; providing health care information via an interactive web site featuring technology that enables users to enter, access, track, monitor and generate addiction treatment information and reports

Goods & Services

(1) Printed products, namely, pamphlets and flyers in the field of opioid dependence and its treatment (1) Providing temporary use of a web-based software application for accessing, operating, and using a treatment participant engagement portal via an interactive website that provides healthcare related information, tools and resources, namely, information relating to health insurance, information relating to financial assistance programs and alternate funding resources in the field of healthcare, copay assistance programs, insurance benefit investigations, insurance coverage reports, insurance case management services, medication savings cards, insurance forms and letters, treatment and health plan provider location services, insurance claim submission and reimbursement assistance services, denied claim review and research services, and insurance verification services, and facilitates communications, connectivity, and workflow with healthcare providers, healthcare organizations and patients in the field of medicine and pharmaceuticals; hosting a website featuring an online community for registered users to participate in discussions and form virtual communities to engage in social networking services in the fields of opioid dependence and schizophrenia, and request and provide feedback on services relating to the treatment of opioid dependence and schizophrenia (2) Provision of information and advice via a website in the field of opioid dependence and its treatment; provision of information and advice in the field of opioid dependence and its treatment; provision of health care information and advice in the fields of opioid dependence, schizophrenia, and their treatment; provision of pharmaceutical information and advice; providing health care information via an interactive web site featuring technology that enables users to enter, access, track, monitor and generate addiction treatment information and reports

Goods & Services

Printed products, namely, pamphlets and flyers in the field of opioid dependence and its treatment

Goods & Services

Providing temporary use of a web-based software application for accessing, operating, and using a treatment participant engagement portal; Computer services, namely, creating an online community for registered users to participate in discussions and request and provide feedback; providing an interactive web site featuring technology that enables users to enter, access, track, monitor and generate addiction treatment information and reports Provision of medical information and advice via a website in the field of opioid dependence and its treatment; Provision of medical information and advice in the field of opioid dependence and its treatment; Provision of health care information and advice; Provision of pharmaceutical information and advice for medical purposes

Goods & Services

Providing temporary use of a web-based software application for accessing, operating, and using a treatment participant engagement portal; Computer services, namely, creating an online community for registered users to participate in discussions and request and provide feedback; providing an interactive web site featuring technology that enables users to enter, access, track, monitor and generate addiction treatment information and reports Provision of medical information and advice via a website in the field of opioid dependence and its treatment; Provision of medical information and advice in the field of opioid dependence and its treatment; Provision of health care information and advice; Provision of pharmaceutical information and advice for medical purposes

Goods & Services

Printed products, namely, pamphlets and flyers in the field of opioid dependence and its treatment

Abstract

The disclosure provides orally administrable capsules comprising abuse-resistant, pharmaceutical formulations which comprise abuse-susceptible active agents such as opioids. The formulations provide abuse resistance by having a sufficiently high viscosity that substantially prevents the formulation and opioid therein, from being drawn into a syringe, at room temperature or higher, either alone or when mixed with water or other liquids.

IPC Classes  ?

• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine

Abstract

min ratio less than 200 and lag time less than 0.2.

IPC Classes  ?

• A61K 9/14 - Particulate form, e.g. powders
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 9/06 - OintmentsBases therefor
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes

Abstract

Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising an opioid receptor antagonist, are provided. Methods of treating opioid overdose or its symptoms with the inventive drug products are also provided.

IPC Classes  ?

• A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
• A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
• A61F 13/00 - Bandages or dressingsAbsorbent pads
• A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61M 15/08 - Inhaling devices inserted into the nose
• A61M 11/00 - Sprayers or atomisers specially adapted for therapeutic purposes

Abstract

Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising an opioid receptor antagonist, are provided. Methods of treating opioid overdose or its symptoms with the inventive drug products are also provided.

IPC Classes  ?

• A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
• A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
• A61F 13/00 - Bandages or dressingsAbsorbent pads
• A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/02 - Inorganic compounds
• A61M 11/00 - Sprayers or atomisers specially adapted for therapeutic purposes

Abstract

The disclosure provides methods for the detection and quantification of drugs and drug metabolites in biological samples, such as naloxone, buprenorphine, and norbuprenorphine.

IPC Classes  ?

• G01N 33/94 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving narcotics

Goods & Services

Providing temporary use of a web-based software application for accessing, operating, and using a treatment participant engagement portal; Computer services, namely, creating an online community for registered users to participate in discussions and request and provide feedback; providing an interactive web site featuring technology that enables users to enter, access, track, monitor and generate addiction treatment information and reports

Goods & Services

Printed products, namely, pamphlets and flyers in the field of opioid dependence and its treatment

Goods & Services

Provision of information and advice via a website in the field of opioid dependence and its treatment; provision of information and advice in the field of opioid dependence and its treatment; provision of health care information and advice; provision of pharmaceutical information and advice

Goods & Services

(1) Pharmaceutical preparations for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; medicines for human and veterinary purposes, namely, medicines for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; Pharmaceutical preparations for use in the treatment of chemical addictions (1) Provision of pharmaceutical advice and information about pharmaceuticals used in the treatment and prevention of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment and prevention of co-morbidities associated with substance use disorders, for the treatment and prevention of mental health diseases and disorders, for the treatment and prevention of central nervous system disease and disorders, and for the treatment of pain; health counseling, namely, drug rehabilitation counselling services; provision of health care information and advice, namely, providing information to patients in the field of administering medications, providing medical and scientific research information in the field of pharmaceuticals and clinical trials, and pharmacy advice; provision of pharmaceutical information and advice; providing pharmaceutical information regarding medication information and treatment plans

Goods & Services

Pharmaceutical preparations for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of comorbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; medicines for human and veterinary purposes, namely, medicines for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of comorbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; Pharmaceutical preparations for use in the treatment of chemical addictions. Provision of pharmaceutical advice and information about pharmaceuticals used in the treatment and prevention of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment and prevention of co-morbidities associated with substance use disorders, for the treatment and prevention of mental health diseases and disorders, for the treatment and prevention of central nervous system disease and disorders, and for the treatment of pain; health counseling; provision of health care information and advice; provision of pharmaceutical information and advice; providing pharmaceutical information regarding medication information and treatment plans.

Abstract

The disclosure provides compounds of formula (I) or pharmaceutically acceptable salts thereof: The disclosure also provides processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them, and their use as modulators of dopamine D3 receptors, such as treating substance abuse or psychiatric diseases.

IPC Classes  ?

• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 25/36 - Opioid-abuse
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings

Abstract

The disclosure provides compounds of formula (I) or pharmaceutically acceptable salts thereof: The disclosure also provides processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them, and their use as modulators of dopamine D3 receptors, such as treating substance abuse or psychiatric diseases.

IPC Classes  ?

• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 25/36 - Opioid-abuse

Abstract

The disclosure provides methods for treating psychiatric diseases, such as schizophrenia, in patients with certain gene polymorphisms using antipsychotic drugs, such as risperidone and paliperidone.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia

Abstract

The disclosure provides extended release pharmaceutical formulations comprising an opioid, particularly buprenorphine, a biocompatible organic solvent, and, optionally, a glycol, for use in the treatment of pain or opioid dependence. The pharmaceutical formulations are in the form of a pharmaceutical solution.

IPC Classes  ?

• A61K 9/08 - Solutions
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Abstract

The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.

IPC Classes  ?

• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/4748 - QuinolinesIsoquinolines forming part of bridged ring systems
• A61K 31/00 - Medicinal preparations containing organic active ingredients

Abstract

Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising an opioid receptor antagonist, are provided. Methods of treating opioid overdose or its symptoms with the inventive drug products are also provided.

IPC Classes  ?

• A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
• A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
• A61F 13/00 - Bandages or dressingsAbsorbent pads
• A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61K 9/08 - Solutions
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61M 11/00 - Sprayers or atomisers specially adapted for therapeutic purposes
• A61K 47/02 - Inorganic compounds
• A61M 15/08 - Inhaling devices inserted into the nose

Goods & Services

(1) Pharmaceutical preparations for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; medicines for human and veterinary purposes, namely, medicines for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; pharmaceutical preparations for use in the treatment of chemical addictions (1) Provision of pharmaceutical advice and information about pharmaceuticals used in the treatment and prevention of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment and prevention of co-morbidities associated with substance use disorders, for the treatment and prevention of mental health diseases and disorders, for the treatment and prevention of central nervous system disease and disorders, and for the treatment of pain; health counseling, namely drug addiction and rehabilitation counselling services; provision of health care information and advice in the field of drug addiction and rehabilitation; provision of pharmaceutical information and advice; providing pharmaceutical information regarding medication information and treatment plans

Goods & Services

(1) Pharmaceutical preparations for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; medicines for human and veterinary purposes, namely, medicines for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; pharmaceutical preparations for use in the treatment of chemical addictions (1) Provision of pharmaceutical advice and information about pharmaceuticals used in the treatment and prevention of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment and prevention of co-morbidities associated with substance use disorders, for the treatment and prevention of mental health diseases and disorders, for the treatment and prevention of central nervous system disease and disorders, and for the treatment of pain; health counseling, namely drug addiction and rehabilitation counselling services; provision of health care information and advice in the field of drug addiction and rehabilitation; provision of pharmaceutical information and advice; providing pharmaceutical information regarding medication information and treatment plans

Goods & Services

Pharmaceutical preparations for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; medicines for human and veterinary purposes, namely, medicines for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; Pharmaceutical preparations for use in the treatment of chemical addictions. Provision of pharmaceutical advice and information about pharmaceuticals used in the treatment and prevention of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment and prevention of co-morbidities associated with substance use disorders, for the treatment and prevention of mental health diseases and disorders, for the treatment and prevention of central nervous system disease and disorders, and for the treatment of pain; health counseling; provision of health care information and advice; provision of pharmaceutical information and advice; providing pharmaceutical information regarding medication information and treatment plans.

Abstract

Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising an opioid receptor antagonist, are provided. Methods of treating opioid overdose or its symptoms with the inventive drug products are also provided.

IPC Classes  ?

• A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
• A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
• A61F 13/00 - Bandages or dressingsAbsorbent pads
• A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
• A61M 11/00 - Sprayers or atomisers specially adapted for therapeutic purposes
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61K 47/02 - Inorganic compounds
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 9/08 - Solutions
• A61M 15/08 - Inhaling devices inserted into the nose

Abstract

The disclosure provides compounds having formula (I), wherein the substituents are as defined herein. The compounds are useful for modulating the dopamine D3 receptor and for treating conditions associated therewith, such as addictions, drug dependency, and psychiatric conditions.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• C07D 498/04 - Ortho-condensed systems
• A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
• A61P 25/30 - Drugs for disorders of the nervous system for treating abuse or dependence

Abstract

The disclosure provides compounds having formula (I), wherein the substituents are as defined herein. The compounds are useful for modulating the dopamine D3 receptor and for treating conditions associated therewith, such as addictions, drug dependency, and psychiatric conditions.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
• A61P 25/30 - Drugs for disorders of the nervous system for treating abuse or dependence
• C07D 498/04 - Ortho-condensed systems